Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
Top Cited Papers
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 362 (9386) , 777-781
- https://doi.org/10.1016/s0140-6736(03)14285-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure—Assessment of Reduction in Mortality and morbidity (CHARM) programmeEuropean Journal of Heart Failure, 2003
- Burden of Systolic and Diastolic Ventricular Dysfunction in the CommunityJAMA, 2003
- A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart FailureNew England Journal of Medicine, 2001
- Ramipril and the Development of DiabetesJAMA, 2001
- Effect of Carvedilol on Survival in Severe Chronic Heart FailureNew England Journal of Medicine, 2001
- Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart FailureJAMA, 2000
- Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk PatientsNew England Journal of Medicine, 2000
- Candesartan in heart failure—assessment of reduction in mortality and morbidity (CHARM): Rationale and designJournal of Cardiac Failure, 1999
- The Effect of Digoxin on Mortality and Morbidity in Patients with Heart FailureNew England Journal of Medicine, 1997
- Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart FailureJAMA, 1995